Profile data is unavailable for this security.
About the company
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
- Revenue in USD (TTM)183.88m
- Net income in USD-85.78m
- Incorporated1990
- Employees229.00
- LocationGeron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 473-7700
- Fax+1 (302) 655-5049
- Websitehttps://www.geron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc | 113.63m | 28.02m | 904.79m | 119.00 | 13.26 | 8.21 | 30.88 | 7.96 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 906.34m | 62.00 | -- | 2.81 | -- | 153.18 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 906.44m | 162.00 | -- | 6.14 | -- | 6.35 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Maravai Lifesciences Holdings Inc | 185.74m | -130.77m | 928.01m | 435.00 | -- | 4.35 | -- | 5.00 | -0.9059 | -0.9059 | 1.29 | 0.8296 | 0.2088 | 3.35 | 5.80 | 426,995.40 | -25.95 | 4.29 | -36.49 | 5.56 | 18.30 | 68.51 | -124.24 | 13.71 | 5.69 | -7.54 | 0.4642 | 0.00 | -28.34 | -8.15 | 9.72 | -- | -12.34 | -- |
| MannKind Corp | 348.97m | 6.70m | 935.08m | 592.00 | 157.17 | -- | 49.26 | 2.68 | 0.0193 | 0.0193 | 1.12 | -0.1658 | 0.5885 | 2.45 | 6.56 | 589,469.60 | 1.13 | -7.58 | 1.44 | -9.71 | 77.80 | 70.19 | 1.92 | -14.56 | 1.50 | 1.31 | 1.09 | -- | 22.23 | 39.89 | -78.75 | -- | -0.9285 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 944.63m | 111.00 | -- | 2.09 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| Personalis Inc | 69.65m | -81.27m | 947.96m | 260.00 | -- | 3.55 | -- | 13.61 | -0.9088 | -0.9088 | 0.7805 | 2.55 | 0.2305 | 8.92 | 5.72 | 267,876.90 | -26.89 | -30.49 | -30.46 | -34.81 | 22.65 | 27.97 | -116.69 | -118.80 | 6.61 | -- | 0.0197 | -- | -17.69 | -2.40 | 0.0172 | -- | 6.77 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 956.90m | 52.00 | -- | 3.10 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| CareDx Inc | 379.81m | -21.35m | 960.05m | 761.00 | -- | 3.15 | -- | 2.53 | -0.3943 | -0.3943 | 7.09 | 5.95 | 0.84 | 5.33 | 7.08 | 499,086.70 | -4.72 | -10.84 | -5.89 | -12.94 | 67.55 | 66.23 | -5.62 | -16.52 | 2.56 | -- | 0.00 | -- | 13.79 | 14.59 | -140.64 | -- | -8.66 | -- |
| Fortrea Holdings Inc | 2.72bn | -986.20m | 987.36m | 14.30k | -- | 1.74 | -- | 0.3626 | -10.90 | -10.90 | 29.66 | 6.05 | 0.8653 | -- | 4.36 | 190,447.50 | -31.33 | -5.20 | -44.50 | -6.52 | 18.50 | 20.89 | -36.21 | -7.39 | -- | -0.2587 | 0.6514 | -- | 1.00 | 1.09 | -263.24 | -- | 0.9806 | -- |
| Geron Corp | 183.88m | -85.78m | 989.45m | 229.00 | -- | 4.43 | -- | 5.38 | -0.1287 | -0.1287 | 0.2759 | 0.3503 | 0.3159 | -- | -- | -- | -14.74 | -38.49 | -17.83 | -48.98 | 97.42 | -- | -46.65 | -267.01 | -- | -3.70 | -- | -- | 138.83 | 273.49 | 50.86 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 993.09m | 50.00 | -- | 3.41 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.21 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.01bn | 35.00 | -- | 4.81 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 1.01bn | -- | -- | -- | -- | 182.19 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Geron Corp's reporting currency: US Dollar USD
43.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 63.77m | 9.99% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 39.68m | 6.22% |
| Deep Track Capital LPas of 31 Dec 2025 | 32.51m | 5.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 31.25m | 4.90% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 26.87m | 4.21% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 23.29m | 3.65% |
| Eversept Partners LPas of 31 Dec 2025 | 17.66m | 2.77% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 15.70m | 2.46% |
| ClearBridge Investments LLCas of 31 Dec 2025 | 14.24m | 2.23% |
| Geode Capital Management LLCas of 31 Dec 2025 | 13.03m | 2.04% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
